NYSE Soins de santé Biotechnologie EVMN

Evommune, Inc.

$ 21.36 3.44 %

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

CEO: Luis C. Pena - https://www.evommune.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$48.4 126.59 %

Recommandation

Buy

DCF

$ -75.52

Loading data...

EVMN vs S&P500

Loading data...

No data available.

Quick ratio

20.36

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-10.12

may indicate that the company is undervalued or has poor growth prospects.

EPS

-2.11

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-195.15 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-28.69 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

5.17

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.03

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-2.39

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
9.10 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
4.56 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.03 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.